Bcal Diagnostics Ltd Net Assets
Bcal Diagnostics Ltd net assets. Based on the latest financial reports, Bcal Diagnostics Ltd (BDX) has net assets worth AU$-826.19K AUD (≈ $-584.58K USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$7.66 Million ≈ $5.42 Million USD) and total liabilities (AU$8.49 Million ≈ $6.01 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See how leveraged is Bcal Diagnostics Ltd's balance sheet to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$-826.19K |
| % of Total Assets | -10.78% |
| Annual Growth Rate | N/A |
| 5-Year Change | -108.57% |
| 10-Year Change | N/A |
| Growth Volatility | 263.78 |
Net Assets of Bcal Diagnostics Ltd (2017–2025)
Net assets of Bcal Diagnostics Ltd from 2017 to 2025. This chart illustrates how Bcal Diagnostics Ltd's net assets have evolved over time, based on quarterly financial data. Also explore net asset momentum of Bcal Diagnostics Ltd to track the company's year-over-year net asset growth rate.
Annual Net Assets for Bcal Diagnostics Ltd (2017–2025)
The table below shows the annual net assets of Bcal Diagnostics Ltd from 2017 to 2025. For live market cap and overall valuation, see market cap of Bcal Diagnostics Ltd.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | AU$-826.19K ≈ $-584.58K |
-113.28% |
| 2024-12-31 | AU$6.22 Million ≈ $4.40 Million |
-27.57% |
| 2023-12-31 | AU$8.59 Million ≈ $6.08 Million |
+64.73% |
| 2022-12-31 | AU$5.21 Million ≈ $3.69 Million |
-45.91% |
| 2021-12-31 | AU$9.64 Million ≈ $6.82 Million |
+167.26% |
| 2020-12-31 | AU$3.61 Million ≈ $2.55 Million |
+721.76% |
| 2019-12-31 | AU$438.92K ≈ $310.56K |
-10.09% |
| 2018-12-31 | AU$488.20K ≈ $345.43K |
+696.47% |
| 2017-12-31 | AU$-81.85K ≈ $-57.91K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Bcal Diagnostics Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3190660000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Bcal Diagnostics Ltd Net Assets Breakdown (December 2025)
Bcal Diagnostics Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$34.01 Million | % |
| Other Comprehensive Income | AU$587.87K | % |
| Total Equity | AU$-826.19K | 100.00% |
Bcal Diagnostics Ltd Competitors by Market Cap
The table below lists competitors of Bcal Diagnostics Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Yw Company Limited
KQ:051390
|
$20.87 Million |
|
Greenyield Bhd
KLSE:0136
|
$20.87 Million |
|
Shenzhen Shenbao Industrial Co Ltd
SHE:200019
|
$20.87 Million |
|
System and Application Technologies Co. Ltd
KQ:060540
|
$20.88 Million |
|
Retractable Technologies Inc
NYSE MKT:RVP
|
$20.86 Million |
|
Beeline Holdings, Inc.
NASDAQ:BLNE
|
$20.86 Million |
|
Astral Asia Bhd
KLSE:7054
|
$20.86 Million |
|
EL. D. Mouzakis S.A
AT:MOYZK
|
$20.86 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bcal Diagnostics Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 6,220,917 to -826,193, a change of -7,047,110 (-113.3%).
- Net loss of 7,371,527 reduced equity.
- Other comprehensive income increased equity by 120,356.
- Other factors increased equity by 204,061.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-7.37 Million | -892.23% |
| Other Comprehensive Income | AU$120.36K | +14.57% |
| Other Changes | AU$204.06K | +24.7% |
| Total Change | AU$- | -113.28% |
Book Value vs Market Value Analysis
This analysis compares Bcal Diagnostics Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | AU$0.00 | AU$0.08 | x |
| 2018-12-31 | AU$0.00 | AU$0.08 | x |
| 2019-12-31 | AU$0.00 | AU$0.08 | x |
| 2020-12-31 | AU$0.02 | AU$0.08 | x |
| 2021-12-31 | AU$0.05 | AU$0.08 | x |
| 2022-12-31 | AU$0.02 | AU$0.08 | x |
| 2023-12-31 | AU$0.03 | AU$0.08 | x |
| 2024-12-31 | AU$0.02 | AU$0.08 | x |
| 2025-12-31 | AU$0.00 | AU$0.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bcal Diagnostics Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4038.97%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-68.01%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | -193.01% | 0.43x | 0.00x | AU$-459.45K |
| 2018 | -88.07% | -166.49% | 0.48x | 1.11x | AU$-478.78K |
| 2019 | -158.65% | -157.51% | 0.54x | 1.87x | AU$-740.25K |
| 2020 | -42.28% | -554.03% | 0.07x | 1.15x | AU$-1.89 Million |
| 2021 | -35.12% | -471.08% | 0.07x | 1.10x | AU$-4.35 Million |
| 2022 | -97.08% | -181.39% | 0.33x | 1.61x | AU$-5.58 Million |
| 2023 | -74.52% | -206.58% | 0.25x | 1.43x | AU$-7.26 Million |
| 2024 | -116.40% | -33465.98% | 0.00x | 1.59x | AU$-7.86 Million |
| 2025 | 0.00% | -4038.97% | 0.02x | 0.00x | AU$-7.29 Million |
Industry Comparison
This section compares Bcal Diagnostics Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $136,188,127
- Average return on equity (ROE) among peers: -32.04%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bcal Diagnostics Ltd (BDX) | AU$-826.19K | 0.00% | N/A | $20.87 Million |
| Australian Clinical Labs Ltd (ACL) | $81.91 Million | 73.70% | 4.80x | $360.33 Million |
| Cryosite Ltd (CTE) | $3.54 Million | 12.84% | 1.57x | $42.13 Million |
| Genetic Signatures Ltd (GSS) | $54.80 Million | 5.59% | 0.09x | $12.54 Million |
| Genetic Technologies Ltd (GTG) | $1.77 Million | -385.79% | 0.84x | $4.01 Million |
| Healius Ltd (HLS) | $1.04 Billion | -62.05% | 1.87x | $249.19 Million |
| Imagion Biosystems Ltd (IBX) | $-2.16 Million | 0.00% | 0.00x | $1.74 Million |
| Integral Diagnostics Ltd (IDX) | $2.90 Million | 117.86% | 1.84x | $468.37 Million |
| Inoviq Ltd (IIQ) | $9.72 Million | -4.58% | 0.08x | $13.45 Million |
| Microba Life Sciences Ltd (MAP) | $32.49 Million | -45.98% | 0.46x | $15.08 Million |
About Bcal Diagnostics Ltd
BCAL Diagnostics Limited, a biotechnology company, engages in developing a novel blood screening test to support the early diagnosis and monitoring of breast cancer in Australia. It is involved in the development and commercialization of BREASTESTplus; Avantect Pancreatic; Avantect Ovarian; BREASTESTplus 2; BREASTEST Monitor; and Avantect multi-cancer test. The company was incorporated in 2010 an… Read more